國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁 到查詢結果 [ subject:"Sarcoma" ]

切換: 標籤 | MARC模式 | ISBD

Immunotherapy of sarcoma

D'Angelo, Sandra P.

Immunotherapy of sarcoma

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Immunotherapy of sarcomaedited by Sandra P. D'Angelo, Seth M. Pollack.
其他作者:	D'Angelo, Sandra P.
出版者:	Cham :Springer International Publishing :2019.
面頁冊數:	vii, 152 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	SarcomaImmunotherapy.
電子資源:	https://doi.org/10.1007/978-3-319-93530-0
ISBN:	9783319935300$q(electronic bk.)

Immunotherapy of sarcoma
Immunotherapy of sarcoma[electronic resource] /edited by Sandra P. D'Angelo, Seth M. Pollack. - Cham :Springer International Publishing :2019. - vii, 152 p. :ill., digital ;24 cm.

Part 1 The Immune Sarcoma Microenvironment -- 1 MDSC, Macrophage and CD47 -- 2 IDO and other inhibitory markers -- 3 Regulatory T cells -- 4 Radiation and sarcoma immunotherapy -- Part 2 Sarcoma Immunotherapeutics -- 5 Oncolytic Virus therapy -- 6 Vaccines -- 7 Immune Checkpoint Blockers -- 8 Adoptive T cell therapy.

This book describes recent progress in the development of immunotherapies for advanced sarcoma, paying special attention to the potential role of manipulations of the sarcoma tumor immune microenvironment in achieving durable remissions. Readers will find a thorough overview of the state of the art in tumor immunology and immunotherapy as they relate to sarcoma. Among the topics addressed are advances in vaccine therapy; the value of adoptive transfer of cytokine-induced natural killer cells; the development of adoptive T cell strategies; and the scope for use of checkpoint inhibitors in patients with sarcoma, mirroring the tremendous breakthroughs made in other malignancies. Detailed information is provided on laboratory and clinical research, with analysis of outcomes of recent trials and identification of key challenges. There is every reason to believe that more effective and less toxic therapies for metastatic sarcoma can be attained by deepening our understanding of cancer immunology and building on the advances in immunotherapy for other solid tumors. In this context, Immunotherapy of Sarcoma will be of high interest for all medical oncologists responsible for the treatment of sarcoma patients.

ISBN: 9783319935300$q(electronic bk.)

Standard No.: 10.1007/978-3-319-93530-0doiSubjects--Topical Terms:

833378
Sarcoma
--Immunotherapy.

LC Class. No.: RC270

Dewey Class. No.: 616.994

Immunotherapy of sarcoma
LDR:02476nmm a2200325 a 4500 001 552586
003 DE-He213
005 20190617162510.0
006 m d
007 cr nn 008maaau
008 191106s2019 gw s 0 eng d
020 $a 9783319935300$q(electronic bk.)
020 $a 9783319935294$q(paper)
024 7 $a 10.1007/978-3-319-93530-0 $2 doi
035 $a 978-3-319-93530-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC270
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
090 $a RC270 $b .I33 2019
245 0 0 $a Immunotherapy of sarcoma $h [electronic resource] / $c edited by Sandra P. D'Angelo, Seth M. Pollack.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a vii, 152 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part 1 The Immune Sarcoma Microenvironment -- 1 MDSC, Macrophage and CD47 -- 2 IDO and other inhibitory markers -- 3 Regulatory T cells -- 4 Radiation and sarcoma immunotherapy -- Part 2 Sarcoma Immunotherapeutics -- 5 Oncolytic Virus therapy -- 6 Vaccines -- 7 Immune Checkpoint Blockers -- 8 Adoptive T cell therapy.
520 $a This book describes recent progress in the development of immunotherapies for advanced sarcoma, paying special attention to the potential role of manipulations of the sarcoma tumor immune microenvironment in achieving durable remissions. Readers will find a thorough overview of the state of the art in tumor immunology and immunotherapy as they relate to sarcoma. Among the topics addressed are advances in vaccine therapy; the value of adoptive transfer of cytokine-induced natural killer cells; the development of adoptive T cell strategies; and the scope for use of checkpoint inhibitors in patients with sarcoma, mirroring the tremendous breakthroughs made in other malignancies. Detailed information is provided on laboratory and clinical research, with analysis of outcomes of recent trials and identification of key challenges. There is every reason to believe that more effective and less toxic therapies for metastatic sarcoma can be attained by deepening our understanding of cancer immunology and building on the advances in immunotherapy for other solid tumors. In this context, Immunotherapy of Sarcoma will be of high interest for all medical oncologists responsible for the treatment of sarcoma patients.
650 0 $a Sarcoma $x Immunotherapy. $3 833378
650 1 4 $a Oncology. $3 195181
650 2 4 $a Immunology. $3 189152
700 1 $a D'Angelo, Sandra P. $3 833376
700 1 $a Pollack, Seth M. $3 833377
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u https://doi.org/10.1007/978-3-319-93530-0
950 $a Medicine (Springer-11650)